Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Clene Inc., 3 years.
Clene Inc.
Director
TriSalus Life Sciences Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
TriSalus Life Sciences Inc. June 12, 2025100.0%
-
Clene Inc. May 21, 202575.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Clene Inc. | Grant or award | +434,451 | $3.28 | $1,424,999 |
| May 14, 2026 | TriSalus Life Sciences Inc. | Grant or award | +28,201 | — | — |
| May 14, 2026 | TriSalus Life Sciences Inc. | Grant or award | +23,065 | — | — |
| Jan 13, 2026 | Clene Inc. | Open-market purchase | +33,333 | $6.50 | $216,665 |
| Jul 31, 2025 | TriSalus Life Sciences Inc. | Derivative conversion | +330,000 | — | — |
| Jan 2, 2025 | TriSalus Life Sciences Inc. | Grant or award | +10,040 | — | — |
| Sep 30, 2024 | Clene Inc. | Open-market purchase | +92,307 | $4.75 | $438,458 |
| Nov 10, 2023 | Clene Inc. | Open-market purchase | +250,002 | $0.41 | $102,501 |
| Aug 10, 2023 | TriSalus Life Sciences Inc. | Other | +931,904 | — | — |
| Jun 16, 2023 | Clene Inc. | Open-market purchase | +1,500,000 | $0.80 | $1,200,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.